The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease

Author： Matters Gail   Harms John   McGovern Christopher   Fitzpatrick Leo   Parikh Anuj   Nilo Nicholas   Smith Jill  

Publisher： Informa Healthcare

ISSN： 1547-691X

Source： Journal of Immunotoxicology, Vol.5, Iss.2, 2008-04, pp. : 179-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Regulatory role of mature B cells in a murine model of inflammatory bowel disease

By Mizoguchi E.   Mizoguchi A.   Preffer F.I.   Bhan A.K.  

International Immunology, Vol. 12, Iss. 5, 2000-05 ,pp. : 597-605

Oxford University Press

Access to resources Recommend Favorite

Medical Management of Inflammatory Bowel Disease in the New Millennium

By Lombardi Daniel A.   Feller Edward R.   Shah Samir A.  

Comprehensive Therapy, Vol. 28, Iss. 1, 2002-03 ,pp. : 39-49

Humana Press, Inc

Access to resources Recommend Favorite

Utility of Screening for Chronic Granulomatous Disease in Patients with Inflammatory Bowel Disease

By Jaggi Preeti  

Journal of Clinical Immunology, Vol. 32, Iss. 1, 2012-02 ,pp. : 78-81

Springer Publishing Company

Access to resources Recommend Favorite

Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease

By Fellermann K.   Herrlinger K.R.   Witthoeft T.   Homann N.   Ludwig D.   Stange E.F.  

Transplantation Proceedings, Vol. 33, Iss. 3, 2001-05 ,pp. : 2247-2248

Elsevier

Access to resources Recommend Favorite

Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease

By Stadnicki A.   Mazurek U.   Plewka D.   Wilczok T.  

International Immunopharmacology, Vol. 3, Iss. 7, 2003-07 ,pp. : 939-944

Elsevier

Access to resources Recommend Favorite